Press Room

Event

Webinar - Particle Engineering of Biopharmaceuticals

Start
Wednesday, December 09, 2020 - 16:00
End
Wednesday, December 09, 2020 - 16:00
Location: online
Biopharmaceuticals Spray Drying Inhalation Drug Product | Hovione

 

 

 

 

 

 

 

 

 

Wednesday, December 9th, 2020

4:00 pm GMT | 11:00 am EDT | 5:00 pm CEST

Registrations to the webinar are subject to approval

 

Watch On-Demand Webinar

 

Speakers
Diana Fernandes, MSc - Scientist, Particle Design & Formulation, R&D Drug Product Development
Paulo Lino, PhD - Scientist, Particle Design & Formulation, R&D Drug Product Development

 

 

Biopharmaceuticals represent the most promising and fastest growing field in the pharmaceutical area. These therapeutics show very high specificity and potency at relatively low concentrations and enable the treatment of otherwise untreatable diseases. Challenges in their delivery arise due to the inherent complex nature of large molecules which requires additional effort to improve bioavailability, shelf-life and patient-compliant delivery.

Freeze-drying has been the gold-standard in the isolation of large molecules in the solid form. Despite its prevalence and track record in the industry, presents several limitations that may be addressed by alternative technologies.

In this webinar we will discuss the advantages and disadvantages of the most promising alternatives to freeze drying with focus on particle engineering methods such as spray drying and spray freeze drying. Alternative methods pose many advantages in terms of costs, throughput and potential for alternate delivery routes. A series of case-studies will also be shown for each of the relevant technologies. Register Now!

 

What can you learn from this webinar?

Want to know how to spray dry your biologic? Our scientists will share their views and tell you how.

 

Watch On-Demand Webinar

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article
Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
Hovione commitment to setting SBTs in line with the Paris Agreement

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of Hovione´s global expansion plans and marks a significant milestone in advancing Hovione's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote Hovione's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores Hovione's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how Hovione can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
Hovione proudly announces its collaborative venture with Higuchi.

Hovione forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Also in Events

See All